Free Trial

Sutro Biopharma (STRO) Stock Price, News & Analysis

Sutro Biopharma logo
$0.76 +0.08 (+12.35%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$0.75 -0.01 (-1.83%)
As of 07/2/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sutro Biopharma Stock (NASDAQ:STRO)

Key Stats

Today's Range
$0.69
$0.79
50-Day Range
$0.68
$1.30
52-Week Range
$0.52
$5.17
Volume
970,178 shs
Average Volume
1.14 million shs
Market Capitalization
$64.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.11
Consensus Rating
Hold

Company Overview

Sutro Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

STRO MarketRank™: 

Sutro Biopharma scored higher than 77% of companies evaluated by MarketBeat, and ranked 246th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sutro Biopharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Sutro Biopharma has only been the subject of 3 research reports in the past 90 days.

  • Read more about Sutro Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Sutro Biopharma are expected to decrease in the coming year, from ($2.92) to ($2.95) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sutro Biopharma is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sutro Biopharma is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sutro Biopharma has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sutro Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    9.29% of the float of Sutro Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sutro Biopharma has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Sutro Biopharma has recently increased by 34.28%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Sutro Biopharma does not currently pay a dividend.

  • Dividend Growth

    Sutro Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.29% of the float of Sutro Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sutro Biopharma has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Sutro Biopharma has recently increased by 34.28%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Sutro Biopharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • Search Interest

    3 people have searched for STRO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sutro Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.60% of the stock of Sutro Biopharma is held by insiders.

  • Percentage Held by Institutions

    96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sutro Biopharma's insider trading history.
Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright
See More Headlines

STRO Stock Analysis - Frequently Asked Questions

Sutro Biopharma's stock was trading at $1.84 on January 1st, 2025. Since then, STRO shares have decreased by 58.5% and is now trading at $0.7640.
View the best growth stocks for 2025 here
.

Sutro Biopharma, Inc. (NASDAQ:STRO) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.28. The business had revenue of $17.40 million for the quarter, compared to the consensus estimate of $11.61 million. Sutro Biopharma had a negative net margin of 373.66% and a negative trailing twelve-month return on equity of 347.60%.

Sutro Biopharma (STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD).

Company Calendar

Last Earnings
5/08/2025
Today
7/02/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:STRO
Fax
N/A
Employees
240
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.11
High Stock Price Target
$17.00
Low Stock Price Target
$0.80
Potential Upside/Downside
+700.3%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$227.46 million
Net Margins
-373.66%
Pretax Margin
-370.06%

Debt

Sales & Book Value

Annual Sales
$62.04 million
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
1.41

Miscellaneous

Free Float
79,478,000
Market Cap
$64.53 million
Optionable
Optionable
Beta
1.64
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:STRO) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners